HONG KONG – A Chinese biotech company has moved its innovative rabies vaccine into human trials in Singapore, with the hope of making therapy less dependent on the assistance of immunoglobulin. Read More

SHANGHAI – Astrazeneca plc, of London, inked an academic collaboration with leading Singaporean research institutes to take advantage of a unique feature of the small but diverse city-state: access to a population that can provide insights into heart failure. Read More

HONG KONG – South Korean pharmaceutical major Green Cross Corp. is expanding its cell therapy business to China's Guizhou Province, where the local government has welcomed the investment in an emerging new therapeutic area with great potential. Read More

Twi Pharmaceuticals Inc., of Taipei, Taiwan, said its fully owned subsidiary, Twi Biotechnology Inc., has received the designation of rare disease drug by the Taiwan FDA for use of AC-203 to treat epidermolysis bullosa simplex (EBS), and is eligible for applying for coverage under National Health Insurance Administration. Twi Biotechnology has developed proprietary formulations to be used topically for EBS. Read More

Beyondspring Pharmaceuticals Inc. literally sprang to life in June 2013 with a phase II cancer compound already in hand. In the second quarter, the company's lead compound, plinabulin, is set to enter a pivotal phase III trial in patients with non-small-cell lung cancer (NSCLC), a notoriously obstinate indication. Read More